Curis Inc CRIS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:23 PM EDT
16.03quote price arrow down-0.48 (-2.91%)
Volume
6,433
52 week range
3.80 - 19.60
Loading...
  • Open16.31
  • Day High16.65
  • Day Low15.90
  • Prev Close16.51
  • 52 Week High19.60
  • 52 Week High Date05/15/23
  • 52 Week Low3.80
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap94.482M
  • Shares Out5.89M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta3.55
  • YTD % Change26.75

KEY STATS

  • Open16.31
  • Day High16.65
  • Day Low15.90
  • Prev Close16.51
  • 52 Week High19.60
  • 52 Week High Date05/15/23
  • 52 Week Low3.80
  • 52 Week Low Date10/25/23
  • Market Cap94.482M
  • Shares Out5.89M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta3.55
  • YTD % Change26.75

RATIOS/PROFITABILITY

  • EPS (TTM)-8.68
  • P/E (TTM)-1.85
  • Fwd P/E (NTM)-2.26
  • EBITDA (TTM)-48.919M
  • ROE (TTM)-207.29%
  • Revenue (TTM)9.812M
  • Gross Margin (TTM)97.60%
  • Net Margin (TTM)-486.45%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Curis Inc

 

Profile

MORE
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in...
Martyn Greenacre
Independent Chairman of the Board
James Dentzer
President, Chief Executive Officer, Director
Diantha Duvall
Chief Financial Officer
Address
128 Spring Street, 4 Maguire Road
Lexington, MA
02421
United States

Top Peers

SYMBOLLASTCHG%CHG
CLSD
Clearside Biomedical Inc
1.23-0.12-8.89%
AFMD
Affimed NV
5.17-0.07-1.24%
JAGX
Jaguar Health Inc
0.298-0.0115-3.7157%
CUE
Cue Biopharma Inc
1.65-0.27-14.10%
ARMP
Armata Pharmaceuticals Inc
3.00-0.26-7.98%